A review of Project Orbis: An initiative enabling faster patient access to cancer therapies

cancer therapy

Source: Adobe stock

Project Orbis was initiated on 17 September 2019 by the US FDA to provide a framework for the concurrent submission and review of innovative oncology products among international regulatory authorities. The focus of the initiative is on high impact cancer treatments targeting unmet needs or providing significant benefit over existing therapies. The agencies participating in Project Orbis include Australia (TGA), Canada (Health Canada), the UK (MHRA), Japan (PDMA), Singapore (HSA) and Brazil (ANVISA).

This list continues to expand. By participating in Project Orbis, other regulatory authorities can benefit by sharing information and collaborating so that treatments can receive speedier approvals in countries other than the US. All participation is voluntary and there are no requirements that labeling or indications must match between the authorities. In the first 12 months of the project, 38 approvals were granted from multiple regulatory authorities.

How to read this journal article 

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.


Free access to selected content

Register now to continue to access industry news, editorials and podcasts plus one member-only journal article each month.

  • Create your own library to save your favourite content.
Create a free account

2. Members login

Already a TOPRA member?

Log-in now using your MyTOPRA credentials, for unlimited access to all Regulatory Rapporteur journal articles, the online archive and latest industry news and podcasts.



Special offer on
TOPRA membership

Join TOPRA today and get membership until the end of 2025 for the exclusive rate of £290.

In addition to unlimited access to Regulatory Rapporteur content, as a TOPRA member you will also be able to enjoy a wide range of benefits including career boosting resources, savings on our events and training, and access to our regional networks and special interest groups.

This offer ends 31 July 2024

Become a member